123 related articles for article (PubMed ID: 37708916)
21. LY294002 and metformin cooperatively enhance the inhibition of growth and the induction of apoptosis of ovarian cancer cells.
Li C; Liu VW; Chan DW; Yao KM; Ngan HY
Int J Gynecol Cancer; 2012 Jan; 22(1):15-22. PubMed ID: 22080879
[TBL] [Abstract][Full Text] [Related]
22. Xanthotoxol suppresses non-small cell lung cancer progression and might improve patients' prognosis.
Lin X; Liu J; Zou Y; Tao C; Chen J
Phytomedicine; 2022 Oct; 105():154364. PubMed ID: 35932608
[TBL] [Abstract][Full Text] [Related]
23. Positive feedback loop of FAM83A/PI3K/AKT/c-Jun induces migration, invasion and metastasis in hepatocellular carcinoma.
Liu C; Peng X; Li Y; Liu S; Hou R; Zhang Y; Zuo S; Liu Z; Luo R; Li L; Fang W
Biomed Pharmacother; 2020 Mar; 123():109780. PubMed ID: 31901550
[TBL] [Abstract][Full Text] [Related]
24. CAF-derived HGF promotes cell proliferation and drug resistance by up-regulating the c-Met/PI3K/Akt and GRP78 signalling in ovarian cancer cells.
Deying W; Feng G; Shumei L; Hui Z; Ming L; Hongqing W
Biosci Rep; 2017 Apr; 37(2):. PubMed ID: 28258248
[TBL] [Abstract][Full Text] [Related]
25. Echinacoside inhibits the proliferation, migration, invasion and angiogenesis of ovarian cancer cells through PI3K/AKT pathway.
Liu J; Tang N; Liu N; Lei P; Wang F
J Mol Histol; 2022 Apr; 53(2):493-502. PubMed ID: 35325326
[TBL] [Abstract][Full Text] [Related]
26. ZIP10 drives osteosarcoma proliferation and chemoresistance through ITGA10-mediated activation of the PI3K/AKT pathway.
Li H; Shen X; Ma M; Liu W; Yang W; Wang P; Cai Z; Mi R; Lu Y; Zhuang J; Jiang Y; Song Y; Wu Y; Shen H
J Exp Clin Cancer Res; 2021 Oct; 40(1):340. PubMed ID: 34706747
[TBL] [Abstract][Full Text] [Related]
27. Suppression of SPIN1-mediated PI3K-Akt pathway by miR-489 increases chemosensitivity in breast cancer.
Chen X; Wang YW; Xing AY; Xiang S; Shi DB; Liu L; Li YX; Gao P
J Pathol; 2016 Aug; 239(4):459-72. PubMed ID: 27171498
[TBL] [Abstract][Full Text] [Related]
28. Upregulated microRNA-15b alleviates ovarian cancer through inhitbition of the PI3K/Akt pathway by targeting LPAR3.
Li GC; Qin XL; Song HH; Li YN; Qiu YY; Cui SC; Wang YS; Wang H; Gong JL
J Cell Physiol; 2019 Dec; 234(12):22331-22342. PubMed ID: 31140597
[TBL] [Abstract][Full Text] [Related]
29. MiRNAs and their interplay with PI3K/AKT/mTOR pathway in ovarian cancer cells: a potential role in platinum resistance.
Gasparri ML; Besharat ZM; Farooqi AA; Khalid S; Taghavi K; Besharat RA; Sabato C; Papadia A; Panici PB; Mueller MD; Ferretti E
J Cancer Res Clin Oncol; 2018 Dec; 144(12):2313-2318. PubMed ID: 30109500
[TBL] [Abstract][Full Text] [Related]
30. LDLR promotes autophagy-mediated cisplatin resistance in ovarian cancer associated with the PI3K/AKT/mTOR signaling pathway.
Liu L; Sun YH; An R; Cheng RJ; Li N; Zheng JH
Kaohsiung J Med Sci; 2023 Aug; 39(8):779-788. PubMed ID: 37218642
[TBL] [Abstract][Full Text] [Related]
31. LAIR-1 suppresses cell growth of ovarian cancer cell via the PI3K-AKT-mTOR pathway.
Liu Y; Ma L; Shangguan F; Zhao X; Wang W; Gao Z; Zhou H; Qu G; Huang Y; An J; Xue J; Yang S; Cao Q
Aging (Albany NY); 2020 Sep; 12(16):16142-16154. PubMed ID: 32628130
[TBL] [Abstract][Full Text] [Related]
32. UBE2S promotes the development of ovarian cancer by promoting PI3K/AKT/mTOR signaling pathway to regulate cell cycle and apoptosis.
Zhang M; Liu Y; Yin Y; Sun Z; Wang Y; Zhang Z; Li F; Chen X
Mol Med; 2022 Jun; 28(1):62. PubMed ID: 35658829
[TBL] [Abstract][Full Text] [Related]
33. A novel mechanism of cannabidiol in suppressing ovarian cancer through LAIR-1 mediated mitochondrial dysfunction and apoptosis.
Ma L; Zhang H; Liu C; Liu M; Shangguan F; Liu Y; Yang S; Li H; An J; Song S; Cao Q; Qu G
Environ Toxicol; 2023 May; 38(5):1118-1132. PubMed ID: 36810933
[TBL] [Abstract][Full Text] [Related]
34. Methyl lucidone induces apoptosis and G
Yoon JH; Shin JW; Pham TH; Choi YJ; Ryu HW; Oh SR; Oh JW; Yoon DY
Pharm Biol; 2020 Dec; 58(1):51-59. PubMed ID: 31875458
[No Abstract] [Full Text] [Related]
35. Dimeric oxyberberine CT4-1 targets LINC02331 to induce cytotoxicity and inhibit chemoresistance via suppressing Wnt/β-catenin signaling in hepatocellular carcinoma.
Lin X; Chen J; Li X; Chen D; Luo K; Deng Y; Yang D; Huang Z; Tao C
Arch Toxicol; 2023 Jun; 97(6):1627-1647. PubMed ID: 37120773
[TBL] [Abstract][Full Text] [Related]
36. Role of PI3K and AKT specific isoforms in ovarian cancer cell migration, invasion and proliferation through the p70S6K1 pathway.
Meng Q; Xia C; Fang J; Rojanasakul Y; Jiang BH
Cell Signal; 2006 Dec; 18(12):2262-71. PubMed ID: 16839745
[TBL] [Abstract][Full Text] [Related]
37. Rab25 is responsible for phosphoinositide 3-kinase/AKT‑mediated cisplatin resistance in human epithelial ovarian cancer cells.
Fan Y; Wang L; Han X; Liu X; Ma H
Mol Med Rep; 2015 Mar; 11(3):2173-8. PubMed ID: 25405658
[TBL] [Abstract][Full Text] [Related]
38. DMBT1 suppresses cell proliferation, migration and invasion in ovarian cancer and enhances sensitivity to cisplatin through galectin-3/PI3k/Akt pathway.
Ma N; Zhao Y
Cell Biochem Funct; 2020 Aug; 38(6):801-809. PubMed ID: 32424818
[TBL] [Abstract][Full Text] [Related]
39. Long noncoding RNA-JPX predicts the poor prognosis of ovarian cancer patients and promotes tumor cell proliferation, invasion and migration by the PI3K/Akt/mTOR signaling pathway.
Li J; Feng L; Tian C; Tang YL; Tang Y; Hu FQ
Eur Rev Med Pharmacol Sci; 2018 Dec; 22(23):8135-8144. PubMed ID: 30556851
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of doxorubicin-induced HER3-PI3K-AKT signalling enhances apoptosis of ovarian cancer cells.
Bezler M; Hengstler JG; Ullrich A
Mol Oncol; 2012 Oct; 6(5):516-29. PubMed ID: 22841590
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
